Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD38 Antibody for APS with Secondary Thrombocytopenia
NCT05983952Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in antiphospholipid syndrome (APS), Thrombocytopenia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
antiphospholipid syndrome (APS)Thrombocytopenia
Beyond the preview
Go deeper on NCT05983952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983952.